Prothena Corporation plc has announced results from its Phase 1 ASCENT clinical program, which evaluated the anti-amyloid beta (Aβ) antibody PRX012 in participants with early symptomatic Alzheimer's disease. The program included several trials: ASCENT-1, a single-ascending-dose trial; ASCENT-2, a multiple-dose trial; and ASCENT-3, an open-label extension trial. The results demonstrated that PRX012, administered as a once-monthly subcutaneous injection, exhibited stable pharmacokinetics, low levels of anti-drug antibodies, and reduced injection site reactions. It also showed dose- and time-dependent reductions in amyloid plaque. However, the study noted higher rates of ARIA-E, a type of brain swelling, compared to other FDA-approved anti-Aβ antibodies. Prothena plans to explore potential partnerships to further develop PRX012 and its preclinical PRX012-TfR (transferrin receptor) antibody. The company does not intend to publicly share additional data from the ASCENT program at this time.